Tired Brain, Low Mood? It Could Be Your Mitochondria
Quick Answer
Chronic tiredness, brain fog, and low mood may be linked to impaired mitochondrial function. Mitochondria produce adenosine triphosphate (ATP), the cell’s primary energy currency, and the brain consumes approximately 20% of total body energy output. When mitochondrial ATP production is disrupted, neurotransmitter signalling, inflammation regulation, and cognitive performance can be affected, potentially contributing to mood and fatigue symptoms (1-6).
Persistent low mood, brain fog, and mental fatigue may be linked to impaired mitochondrial function, particularly when these symptoms occur alongside chronic fatigue, poor stress tolerance, or unexplained physical exhaustion (1-3).
Mitochondria generate cellular energy in the form of adenosine triphosphate (ATP), which the brain relies on heavily. When energy production is disrupted, neurotransmitter signalling, inflammation regulation, and cognitive performance can be affected — potentially contributing to mood symptoms in some individuals (4-6).
At a Glance
- The human brain consumes approximately 20% of the body’s total energy output despite representing only 2% of body weight, making it highly vulnerable to mitochondrial dysfunction (6).
- Research by Anderson and Maes (2014) and Scaini et al. (2016) has linked impaired mitochondrial function with depression, bipolar disorder, and cognitive fatigue in specific populations (1, 2).
- Neurotransmitter synthesis, release, and reuptake — including serotonin and dopamine pathways — are energy-dependent processes that may be compromised when ATP availability is reduced (3, 8).
- Standard blood tests do not directly assess mitochondrial ATP production or oxidative stress markers, which may leave cellular energy deficits undetected (5, 9).
- Organic acids testing and functional blood chemistry can help identify metabolic bottlenecks associated with mitochondrial underperformance (9).
- Addressing mitochondrial health through functional medicine is intended to complement — not replace — psychological or psychiatric care (1-3).
Core Concept: Why Brain Energy Matters for Mood
Mitochondria are intracellular organelles responsible for producing ATP through oxidative phosphorylation, the primary energy currency of the body. Although the brain represents only around 2% of total body weight, it consumes approximately 20% of the body’s total energy output, as documented by Martin Picard and Bruce McEwen at Columbia University and Rockefeller University (6).
Because of this high demand, even subtle impairments in cellular energy metabolism may disproportionately affect cognitive and emotional function. This includes pathways related to cellular energy metabolism and methylation, which influence mitochondrial efficiency and neurological function.
Research published in Progress in Neuro-Psychopharmacology and Biological Psychiatry and BMC Medicine has increasingly linked mitochondrial dysfunction with depression, anxiety, cognitive fatigue, and neuroinflammation in specific populations (1-4, 7).
This does not imply that all mood disorders are caused by mitochondrial dysfunction. Rather, impaired cellular energy production may represent an under-recognised contributing factor in complex, chronic, or treatment-resistant cases.
Neurotransmitter Signalling and Energy
Neurotransmitter synthesis, release, and reuptake are all energy-dependent processes. When ATP availability is reduced, neurotransmitter signalling — including serotonin, dopamine, and norepinephrine pathways — may become inefficient, even when neurotransmitter levels appear adequate on standard assessment (3, 8).
Why Conventional Mental Health Care May Miss Mitochondrial Factors
Standard mental health assessment appropriately focuses on psychological history, symptom patterns, and — where indicated — pharmacological modulation of neurotransmitters via selective serotonin reuptake inhibitors (SSRIs) or serotonin-norepinephrine reuptake inhibitors (SNRIs). This approach is effective and essential for many individuals.
However, routine mental health care rarely evaluates cellular energy metabolism, oxidative stress, or mitochondrial efficiency. Standard blood tests — including full blood count (FBC), thyroid stimulating hormone (TSH), and basic metabolic panels — do not directly assess ATP production or metabolic bottlenecks that influence neuronal energy availability (5, 9).
As a result, individuals experiencing overlapping symptoms — such as depression, chronic fatigue, exercise intolerance, or cognitive fog — may be told their results are “normal,” despite ongoing functional impairment. This reflects current testing limitations rather than a failure of care.
How Mitochondrial Dysfunction Can Influence Mental Health
Impaired mitochondrial function can trigger several downstream effects that may contribute to mood and cognitive symptoms. Gardner and Boles (2011) described these interconnected mechanisms in their research published in Progress in Neuro-Psychopharmacology and Biological Psychiatry (3).
| Mechanism | Effect on Brain Function | Associated Symptoms | References |
|---|---|---|---|
| Reduced ATP production | Limited neuronal firing capacity and cognitive endurance | Brain fog, mental fatigue | (3, 6) |
| Increased oxidative stress | Damage to neuronal membranes and enzymes | Cognitive decline, neuroinflammation | (7, 8) |
| Low-grade neuroinflammation | Altered cytokine signalling (IL-6, TNF-alpha) | Low mood, reduced motivation | (4, 10) |
| Impaired detoxification | Reduced metabolic clearance via glutathione pathways | Cognitive fog, chemical sensitivity | (9) |
| Disrupted neurotransmitter synthesis | Reduced serotonin and dopamine production | Depression, anhedonia | (3, 8) |
These mechanisms have been observed in subsets of individuals with major depressive disorder (MDD), bipolar disorder, chronic fatigue syndrome (CFS/ME), and neurodegenerative conditions, although the degree of involvement varies between individuals (1-3, 9, 11).
Why Antidepressants May Help Some People and Not Others
Antidepressant medications, including SSRIs such as fluoxetine and sertraline, can be effective and appropriate, particularly in moderate to severe depression. However, Parker and Crawford (2014) noted in Acta Psychiatrica Scandinavica that response rates vary, and a significant proportion of individuals experience only partial or minimal benefit (15).
Emerging research suggests that altered energy metabolism and inflammatory signalling — including elevated pro-inflammatory cytokines such as interleukin-6 (IL-6) and tumour necrosis factor-alpha (TNF-alpha) — may limit the brain’s capacity to utilise neurotransmitters efficiently, even when their availability is pharmacologically increased (1, 3, 4).
This does not invalidate antidepressant therapy. Instead, it highlights that additional physiological contributors may need to be addressed in some individuals alongside standard mental health care.
Solution Explained: A Functional, Systems-Based Assessment
At Elemental Health and Nutrition in Adelaide, South Australia, mitochondrial health is assessed indirectly using pattern-based functional testing rather than a single diagnostic marker. This approach is led by Rohan Smith, BHSc Nutritional Medicine, a Functional Medicine Practitioner with over 12 years of clinical experience.
| Assessment Type | What It Evaluates | Relevance to Mitochondria |
|---|---|---|
| Organic acids testing (OAT) | Metabolic intermediates of the Krebs cycle, oxidative stress markers, nutrient cofactors | Identifies bottlenecks in mitochondrial energy pathways (9) |
| Functional blood chemistry | Thyroid (TSH, T3, T4), liver enzymes, glucose regulation, iron studies, inflammatory markers (CRP, ESR) | Detects systemic factors that influence mitochondrial performance |
| Comprehensive gut testing | Microbiome composition, gut permeability markers, pathogen screening | Gut-derived inflammation and nutrient malabsorption can impair mitochondrial function (10) |
| Environmental exposure assessment | Heavy metals (mercury, lead), mould exposure, chemical toxicants | Certain toxins are recognised mitochondrial inhibitors per Douglas Wallace’s research at CHOP (5) |
These tools are used to identify contributing patterns and physiological stressors. They do not diagnose psychiatric conditions and are intended to complement — not replace — psychological or psychiatric care.
When to Consider a Mitochondrial Contribution
A mitochondrial component may be worth exploring when low mood or anxiety occurs alongside several co-presenting features, as described by Morris et al. (2017) in Molecular Neurobiology (11):
- Chronic or unexplained fatigue
- Post-exertional exhaustion (post-exertional malaise)
- Brain fog or cognitive slowing
- Reduced stress tolerance or HPA axis dysregulation
- Multiple nutrient deficiencies (B vitamins, CoQ10, magnesium, iron)
- Limited or short-lived response to standard treatments
Not all individuals will exhibit a mitochondrial contribution, and careful, individualised assessment is required.
Frequently Asked Questions
Key Insights
- The brain is one of the body’s most energy-dependent organs, consuming approximately 20% of total ATP output (6)
- Impaired mitochondrial function may contribute to mood and cognitive symptoms in some individuals (1-4)
- Standard testing does not typically assess cellular energy metabolism or oxidative stress markers
- Organic acids testing and functional blood chemistry can help identify mitochondrial bottlenecks
- A systems-based approach can help identify overlooked contributors to treatment-resistant mood symptoms
- Addressing physiology complements — rather than replaces — psychological care
Citable Takeaways
- The human brain consumes approximately 20% of the body’s total energy output despite representing only 2% of body weight, making it disproportionately vulnerable to mitochondrial dysfunction, according to Picard and McEwen (2018) in Psychosomatic Medicine (6).
- Anderson and Maes (2014) identified mitochondrial dysfunction and immune activation as interconnected contributors to both bipolar disorder and major depressive disorder in a critical review published in Progress in Neuro-Psychopharmacology and Biological Psychiatry (1).
- Naviaux et al. (2016) found distinct metabolic features associated with chronic fatigue syndrome (CFS/ME) through metabolomic analysis, published in the Proceedings of the National Academy of Sciences (9).
- Neurotransmitter synthesis, release, and reuptake — including serotonin and dopamine pathways — are energy-dependent processes that may be compromised when mitochondrial ATP availability is reduced (3, 8).
- Standard blood tests including full blood count and thyroid panels do not directly assess mitochondrial ATP production, oxidative stress, or metabolic bottlenecks that influence neuronal energy availability (5, 9).
- Coenzyme Q10 (CoQ10) supplementation has been associated with improvements in depressive symptoms in a meta-analysis by Allen et al. (2015) published in the Journal of Psychiatric Research (12).
Take the Next Step Toward Better Brain Health
If chronic fatigue, brain fog, or low mood have not responded as expected to conventional approaches, a deeper functional evaluation may be appropriate.
At Elemental Health and Nutrition in Adelaide, Rohan Smith uses evidence-based testing to evaluate mitochondrial health, nutrient status, and metabolic function as part of a personalised, systems-based approach.
References
- Anderson G, Maes M. Mitochondrial dysfunction and immune activation in bipolar disorder and major depressive disorder: a critical review. Prog Neuropsychopharmacol Biol Psychiatry. 2014 Oct 3;54:11-21. doi: 10.1016/j.pnpbp.2014.04.014.
- Scaini G, Rezin GT, Carvalho AF, Streck EL, Berk M, Quevedo J. Mitochondrial dysfunction in mood disorders: insights from human studies. CNS Neurol Disord Drug Targets. 2016;15(4):487-496.
- Gardner A, Boles RG. Beyond the serotonin hypothesis: mitochondria, inflammation and neurodegeneration in major depression and affective spectrum disorders. Prog Neuropsychopharmacol Biol Psychiatry. 2011 Mar 30;35(3):730-743.
- Morris G, Berk M. The many roads to mitochondrial dysfunction in neuroimmune and neuropsychiatric disorders. BMC Med. 2015 Apr 1;13:74.
- Wallace DC. Mitochondrial genetic medicine. Nat Genet. 2018 Dec;50(12):1642-1649.
- Picard M, McEwen BS. Psychological stress and mitochondria: a systematic review. Psychosom Med. 2018 Feb/Mar;80(2):141-153.
- Berk M, Williams LJ, Jacka FN, et al. So depression is an inflammatory disease, but where does the inflammation come from? BMC Med. 2013 Sep 12;11:200.
- Maes M, Kubera M, et al. The role of the inflammatory & oxidative & nitrosative stress (IO&NS) pathways in depression. Prog Neuropsychopharmacol Biol Psychiatry. 2011 Apr 29;35(3):676-692.
- Naviaux RK, et al. Metabolic features of chronic fatigue syndrome. Proc Natl Acad Sci U S A. 2016 Sep 13;113(37):E5472-80.
- Raison CL, Capuron L, Miller AH. Cytokines sing the blues: inflammation and the pathogenesis of depression. Trends Immunol. 2006 Jan;27(1):24-31.
- Morris G, et al. Mitochondrial dysfunction in psychiatric disorders: an update. Mol Neurobiol. 2017 Oct;54(8):5630-5653.
- Allen J, et al. Coenzyme Q10 supplementation in the treatment of depression: a meta-analysis. J Psychiatr Res. 2015;63:16-21.
- Swerdlow RH. Mitochondria in neuroinflammation. Neurotherapeutics. 2007 Jul;4(3):365-377.
- McEwen BS. Protection and damage from acute and chronic stress. Ann N Y Acad Sci. 2004 Dec;1032:1-7.
- Parker G, Crawford J. When antidepressants fail: switching strategies. Acta Psychiatr Scand. 2014 Jun;129(6):401-414.
